Dawn Colburn

695 total citations
20 papers, 524 citations indexed

About

Dawn Colburn is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Dawn Colburn has authored 20 papers receiving a total of 524 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 12 papers in Oncology and 4 papers in Genetics. Recurrent topics in Dawn Colburn's work include Hedgehog Signaling Pathway Studies (8 papers), Oral and gingival health research (4 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Dawn Colburn is often cited by papers focused on Hedgehog Signaling Pathway Studies (8 papers), Oral and gingival health research (4 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Dawn Colburn collaborates with scholars based in United States, United Kingdom and Switzerland. Dawn Colburn's co-authors include Francis J. Giles, Deborah A. Thomas, Richard Graham, Elihu H. Estey, Steve Kornblau, Cynthia L. David, Francis J. Giles, Guillermo Garcia‐Manero, Alexandria T. Phan and H. Kantarjian and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Dawn Colburn

20 papers receiving 500 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dawn Colburn United States 10 252 160 135 80 78 20 524
Carole Ferraro France 5 160 0.6× 83 0.5× 106 0.8× 23 0.3× 41 0.5× 5 510
Haihua Gong United States 7 218 0.9× 98 0.6× 69 0.5× 15 0.2× 69 0.9× 10 572
N. Ciobanu United States 13 101 0.4× 285 1.8× 98 0.7× 14 0.2× 99 1.3× 24 672
Valerie Relias United States 11 139 0.6× 161 1.0× 72 0.5× 29 0.4× 29 0.4× 32 463
Kenneth Washenik United States 5 69 0.3× 52 0.3× 132 1.0× 115 1.4× 47 0.6× 7 409
Martine C. McManus United States 9 176 0.7× 229 1.4× 32 0.2× 57 0.7× 68 0.9× 18 589
Tomas Norman Dam Denmark 14 148 0.6× 116 0.7× 46 0.3× 180 2.3× 64 0.8× 25 710
Dominique Cazals France 9 138 0.5× 247 1.5× 20 0.1× 30 0.4× 143 1.8× 11 525
Sophie Barrett United Kingdom 9 256 1.0× 295 1.8× 32 0.2× 37 0.5× 59 0.8× 18 660
Emanuela Campalani United Kingdom 8 165 0.7× 78 0.5× 53 0.4× 167 2.1× 61 0.8× 14 593

Countries citing papers authored by Dawn Colburn

Since Specialization
Citations

This map shows the geographic impact of Dawn Colburn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dawn Colburn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dawn Colburn more than expected).

Fields of papers citing papers by Dawn Colburn

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dawn Colburn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dawn Colburn. The network helps show where Dawn Colburn may publish in the future.

Co-authorship network of co-authors of Dawn Colburn

This figure shows the co-authorship network connecting the top 25 collaborators of Dawn Colburn. A scholar is included among the top collaborators of Dawn Colburn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dawn Colburn. Dawn Colburn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Dumbrava, Ecaterina E., Idoia Rodríguez, Mohamad A. Salkeni, et al.. (2025). Abstract CT154: BDC-3042, a first-in-class Dectin-2 agonist, in patients with advanced malignancies: Results from the first-in-human dose-escalation study. Cancer Research. 85(8_Supplement_2). CT154–CT154. 1 indexed citations
2.
3.
Sadetsky, Natalia, et al.. (2020). Survival outcomes in an older US population with advanced melanoma and central nervous system metastases: SEER‐Medicare analysis. Cancer Medicine. 9(17). 6216–6224. 5 indexed citations
4.
Zhang, Weijiang, Dawn Colburn, Brian Simmons, et al.. (2020). Absolute Bioavailability of Vemurafenib in Patients With BRAFV600 Mutation–Positive Malignancies. Clinical Pharmacology in Drug Development. 9(4). 496–504. 5 indexed citations
5.
6.
Zhang, Weijiang, Christine McIntyre, Tae Min Kim, et al.. (2018). Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Digoxin in Patients With BRAFV600 Mutation–Positive Metastatic Malignancy. The Journal of Clinical Pharmacology. 58(8). 1067–1073. 11 indexed citations
7.
Abou‐Alfa, Ghassan K., Lionel D. Lewis, Patricia LoRusso, et al.. (2017). Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment. Cancer Chemotherapy and Pharmacology. 80(1). 29–36. 24 indexed citations
8.
9.
Abou‐Alfa, Ghassan K., Lionel D. Lewis, Patricia LoRusso, et al.. (2015). Abstract CT308: Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic dysfunction. Cancer Research. 75(15_Supplement). CT308–CT308. 1 indexed citations
10.
Kabbinavar, Fairooz F., Louis Fehrenbacher, John D. Hainsworth, et al.. (2014). Biomarker Analyses from a Randomized, Placebo-Controlled, Phase IIIb Trial Comparing Bevacizumab with or without Erlotinib as Maintenance Therapy for the Treatment of Advanced Non-Small-Cell Lung Cancer (ATLAS). Journal of Thoracic Oncology. 9(9). 1411–1417. 13 indexed citations
11.
Graham, Richard, Cornelis E. C. A. Hop, Marie T. Borin, et al.. (2012). Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects. British Journal of Clinical Pharmacology. 74(5). 788–796. 49 indexed citations
12.
LoRusso, Patricia, Sarina A. Piha‐Paul, Monica Mita, et al.. (2012). Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug–drug interaction potential. Cancer Chemotherapy and Pharmacology. 71(1). 193–202. 17 indexed citations
13.
LoRusso, Patricia, Antonio Jimeno, Grace K. Dy, et al.. (2011). Pharmacokinetic Dose-Scheduling Study of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors. Clinical Cancer Research. 17(17). 5774–5782. 74 indexed citations
14.
LoRusso, Patricia, Sarina A. Piha‐Paul, A. Dimitrios Colevas, et al.. (2011). Abstract B188: Pharmacokinetic assessment of drug-drug interaction potential when rosiglitazone or combined oral contraceptive is coadministered with vismodegib in patients with locally advanced or metastatic solid tumors.. Molecular Cancer Therapeutics. 10(11_Supplement). B188–B188. 2 indexed citations
15.
LoRusso, Patricia, Antonio Jimeno, Grace K. Dy, et al.. (2011). Abstract 1310: Evaluation of optimal dosing schedule on steady-state pharmacokinetics of orally administered hedgehog pathway inhibitor GDC-0449 in cancer patients. Cancer Research. 71(8_Supplement). 1310–1310. 1 indexed citations
16.
17.
Tsimberidou, Apostolia M., Dawn Colburn, Mary Alma Welch, et al.. (2003). Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders. Cancer Chemotherapy and Pharmacology. 52(3). 229–234. 9 indexed citations
18.
Colburn, Dawn, Deborah A. Thomas, & Francis J. Giles. (2003). Phase II Study of Single Agent Paclitaxel in Adult Patients with Relapsed Acute Lymphocytic Leukemia. Investigational New Drugs. 21(1). 109–111. 9 indexed citations
19.
Colburn, Dawn, et al.. (2002). Skin Infiltration with Chronic Lymphocytic Leukemia is Consistent with a Good Prognosis. Hematology. 7(3). 187–188. 37 indexed citations
20.
Giles, Francis J., H. Kantarjian, Steve Kornblau, et al.. (2001). Mylotarg? (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer. 92(2). 406–413. 203 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Carole Ferraro Breakdown of academic impact, for papers by Haihua Gong Breakdown of academic impact, for papers by N. Ciobanu Breakdown of academic impact, for papers by Valerie Relias Breakdown of academic impact, for papers by Kenneth Washenik Breakdown of academic impact, for papers by Martine C. McManus Breakdown of academic impact, for papers by Tomas Norman Dam Breakdown of academic impact, for papers by Dominique Cazals Breakdown of academic impact, for papers by Sophie Barrett Breakdown of academic impact, for papers by Emanuela Campalani
Rankless by CCL
2026